# EDGAR Filing Document

**Accession Number:** 0000946644
**File Stem:** 0001493152-26-002728
**Filing Date:** 2026-1
**Character Count:** 13158
**Document Hash:** 0c7e54f126f1b70a4aefa32202304807
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-002728.hdr.sgml**: 20260120

**ACCESSION NUMBER**: 0001493152-26-002728

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260120

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260120

**DATE AS OF CHANGE**: 20260120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AIM ImmunoTech Inc.
- **CENTRAL INDEX KEY:** 0000946644
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 520845822
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-27072
- **FILM NUMBER:** 26541096

**BUSINESS ADDRESS:**
- **STREET 1:** 2117 SW HIGHWAY 484
- **CITY:** OCALA
- **STATE:** FL
- **ZIP:** 32801
- **BUSINESS PHONE:** 352-448-7797

**MAIL ADDRESS:**
- **STREET 1:** 2117 SW HIGHWAY 484
- **CITY:** OCALA
- **STATE:** FL
- **ZIP:** 32801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HEMISPHERX BIOPHARMA INC
- **DATE OF NAME CHANGE:** 19950614

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) January 20, 2026**

**AIM IMMUNOTECH INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-27072** | **52-0845822** |
| (state or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |

---

---

| | |
|:---|:---|
| **2117 SW Highway 484** **, Ocala FL** | **34473** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: (**352** **) 448-7797**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| Title of each class | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share AIM | NYSE American |

---

**<u>Item 7.01. Regulation FD Disclosure.</u>**

Furnished herewith as Exhibits 99.1 and 99.2, respectively, are a January 20, 2026 Notice of Change and Modifications of Class E Common Stock Purchase Warrants and a January 20, 2026 Notice of Change and Modifications of Class F Common Stock Purchase Warrants that were sent to the holders of these warrants.

The information, including Exhibits 99.1 and 99.2 referenced herein, are "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, if and to the extent such subsequent filing specifically references the information herein as being incorporated by reference in such filing.

**Cautionary Statement Regarding Forward-Looking Statements**

Some of the statements included in the notices filed herewith may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the notices speak only as of the date of the notices. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date thereof. We are in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in our reports filed with the Securities and Exchange Commission ("SEC") on our website and in our press releases set forth our current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, we cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in our reports filed with the SEC, on our website and in our press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. We cannot assure that our potential foreign operations will not be adversely affected by these risks.

Please review the "Risk Factors" section in our latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. Our filings are available at www.aimimmuno.com. The information found on our website is not incorporated by reference herein and is included for reference purposes only.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

The following exhibits are filed herewith:

---

| | |
|:---|:---|
| Exhibit |  |
| Number | Description |
| 99.1 | ["January 20, 2026 Notice of Change and Modifications of Class E Common Stock Purchase Warrants"](ex99-1.htm) |
| 99.2 | ["January 20, 2026 Notice of Change and Modifications of Class F Common Stock Purchase Warrants"](ex99-2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | AIM ImmunoTech Inc. | AIM ImmunoTech Inc. |
| Date: January 20, 2026 | By | */s/ Thomas K. Equels* |
|  |  | Thomas K. Equels, CEO |

---

## Exhibit 99.1

**Exhibit 99.1**

**January 20, 2026** 

**Notice of Change and Modification of Class E Common Stock Purchase Warrants** 

Pursuant to Section 3(f)(i) of the Class E Common Stock Purchase Warrants of AIM ImmunoTech Inc. (the "<u>Company</u>") issued on June 30, 2025 (the "<u>Warrants</u>"), the Company is required to provide to holders of the Warrants notice by e-mail of any adjustment in the Exercise Price of the Warrants after such adjustment, set forth any resulting adjustment to the number of Warrant Shares and provide a brief statement of the facts requiring such adjustment.

On January 13, 2026, the Company distributed a dividend of one share of its common stock for every 1,000 shares of common stock issued and outstanding as of January 9, 2026 as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (the "<u>Dividend</u>"). The issuance of the Dividend was a Share Combination Event under Section 3(g) of the Warrants.

Section 3(g) of the Warrants provides that upon the occurrence of a stock dividend which is a Share Combination Event and the lowest VWAP during the period (the "<u>Evaluation Period</u>") commencing four consecutive Trading Days immediately preceding and the four consecutive Trading Days commencing on the Share Combination Event Date is less than the Exercise Price of the Warrants then in effect, then the Exercise Price shall be reduced (but in no event increased) to the Event Market Price and the number of shares issuable upon the exercise of the Warrants shall be inversely increased; provided, however, in no event shall the Event Market Price be less than $1.44 (subject to adjustment for reverse and forward stock splits, recapitalizations and similar transactions following the original issuance date of this Warrants).

During the Evaluation Period, the VWAP was below $1.439 (which is the Floor Price after taking into account the Dividend). Since the Exercise Price has reached the Floor Price, and further since the application of Section 3(g) cannot increase the Exercise Price or further lower the Floor Price, Section 3(g) cannot be triggered again and, by its terms, has no further effect on the terms of the Warrants.

As a result, the number of outstanding Warrants has been increased to 5,561,125 and the Exercise Price has been reduced to $1.439 per share of common stock.

Any capitalized term not defined in this Notice has the meaning set forth in the Warrants.

## Exhibit 99.2

**Exhibit 99.2**

**January 20, 2026** 

**Notice of Change and Modification of Class F Common Stock Purchase Warrants** 

Pursuant to Section 3(f)(i) of the Class F Common Stock Purchase Warrants of AIM ImmunoTech Inc. (the "<u>Company</u>") issued on June 30, 2025 (the "<u>Warrants</u>"), the Company is required to provide to holders of the Warrants notice by e-mail of any adjustment in the Exercise Price of the Warrants after such adjustment, set forth any resulting adjustment to the number of Warrant Shares and provide a brief statement of the facts requiring such adjustment.

On January 13, 2026, the Company distributed a dividend of one share of its common stock for every 1,000 shares of common stock issued and outstanding as of January 9, 2026 as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (the "<u>Dividend</u>"). The issuance of the Dividend was a Share Combination Event under Section 3(g) of the Warrants.

Section 3(g) of the Warrants provides that upon the occurrence of a stock dividend which is a Share Combination Event and the lowest VWAP during the period (the "<u>Evaluation Period</u>") commencing four consecutive Trading Days immediately preceding and the four consecutive Trading Days commencing on the Share Combination Event Date is less than the Exercise Price of the Warrants then in effect, then the Exercise Price shall be reduced (but in no event increased) to the Event Market Price and the number of shares issuable upon the exercise of the Warrants shall be inversely increased; provided, however, in no event shall the Event Market Price be less than $1.44 (subject to adjustment for reverse and forward stock splits, recapitalizations and similar transactions following the original issuance date of this Warrants).

During the Evaluation Period, the VWAP was <u>below $1.439 (which</u> is the Floor Price after taking into account the Dividend). Since the Exercise Price has reached the Floor Price, and further since the application of Section 3(g) cannot increase the Exercise Price or further lower the Floor Price, Section 3(g) cannot be triggered again and, by its terms, has no further effect on the terms of the Warrants.

As a result, the number of outstanding Warrants has been increased to 5,561,125 and the Exercise Price has been reduced to $1.439 per share of common stock.

Any capitalized term not defined in this Notice has the meaning set forth in the Warrants.